| Methotrexate compared with mercaptopurine for early induced abortion. | |
| | |
MedLine Citation:
|
PMID: 10362152 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To compare the antimetabolites methotrexate and 6-mercaptopurine as single-agent medical abortifacients using clinical and immunohistochemical analyses. METHODS: Twenty-seven women with gestations less than 7 weeks from the last menstrual period (LMP) were randomized to receive intramuscular methotrexate, 50 mg/m2, or oral 6-mercaptopurine, 200 mg. Forty-six additional women received methotrexate after randomization was discontinued. Women returned at 2-week intervals. Those without fetal cardiac activity were followed until complete abortion. Those with fetal cardiac activity were considered failures and underwent suction abortions. Tissue collected at the time of suction abortion was analyzed with the cell-proliferation immunohistochemical assay Ki-67. RESULTS: All 12 women in the 6-mercaptopurine group had fetal cardiac activity at follow-up and underwent suction abortion; therefore, this arm of the study was discontinued. Six of the 61 women who received methotrexate had fetal cardiac activity at follow-up and also underwent suction abortion. Fetal cardiac activity was present after methotrexate in three of 55 women at less than 6 weeks from the LMP and in three of six between 6 and 7 weeks from the LMP (P < .01). Women who aborted after methotrexate started bleeding on day 19 (standard deviation [SD] 7.8), bled for 9 days (SD 4.0), and used minimal pain medications. Tissues exposed to methotrexate showed decreased Ki-67 activity compared with tissues exposed to 6-mercaptopurine (P = .003). CONCLUSION: In oral doses of 200 mg, 6-mercaptopurine did not induce early abortion. A single intramuscular dose of methotrexate used without prostaglandins induced abortion in most women at gestational ages of less than 6 weeks. Ki-67 activity was lower in a small sample of fetal tissues exposed to methotrexate than in tissues exposed to 6-mercaptopurine. |
| | |
Authors:
|
A R Davis; L Miller; H Tamimi; A Gown |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Obstetrics and gynecology Volume: 93 ISSN: 0029-7844 ISO Abbreviation: Obstet Gynecol Publication Date: 1999 Jun |
Date Detail:
|
Created Date: 1999-07-07 Completed Date: 1999-07-07 Revised Date: 2009-10-26 |
Medline Journal Info:
|
Nlm Unique ID: 0401101 Medline TA: Obstet Gynecol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 904-9 Citation Subset: AIM; IM |
Affiliation:
|
Department of Obstetrics and Gynecology, Columbia University, New York, New York 10032, USA. daviann@cpmc3.cpmc.columbia.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
6-Mercaptopurine
/
therapeutic use* Abortifacient Agents / therapeutic use* Abortion, Induced* Adult Female Fetus / immunology Humans Ki-67 Antigen / analysis Methotrexate / therapeutic use* Placenta / immunology Pregnancy Pregnancy Trimester, First |
| Chemical | |
Reg. No./Substance:
|
0/Abortifacient Agents; 0/Ki-67 Antigen; 50-44-2/6-Mercaptopurine; 59-05-2/Methotrexate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Contraceptive effectiveness of two spermicides: a randomized trial.
Next Document: Patients' understanding of medical risks: implications for genetic counseling.